These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 25693021)

  • 1. First-line crizotinib in ALK-positive lung cancer.
    Solomon BJ; Mok T
    N Engl J Med; 2015 Feb; 372(8):782. PubMed ID: 25693021
    [No Abstract]   [Full Text] [Related]  

  • 2. First-line crizotinib in ALK-positive lung cancer.
    Alkan A; Köksoy EB; Utkan G
    N Engl J Med; 2015 Feb; 372(8):781-2. PubMed ID: 25693023
    [No Abstract]   [Full Text] [Related]  

  • 3. First-line crizotinib in ALK-positive lung cancer.
    Tural D; Kilickap S
    N Engl J Med; 2015 Feb; 372(8):781. PubMed ID: 25693022
    [No Abstract]   [Full Text] [Related]  

  • 4. Targeted therapies: new standard for ALK-positive NSCLC.
    Hutchinson L
    Nat Rev Clin Oncol; 2015 Feb; 12(2):66. PubMed ID: 25560531
    [No Abstract]   [Full Text] [Related]  

  • 5. Crizotinib in ALK-positive lung cancer.
    Girard N
    Lancet Oncol; 2012 Oct; 13(10):962-3. PubMed ID: 22954506
    [No Abstract]   [Full Text] [Related]  

  • 6. Cancer-drug discovery--let's get ready for the next period.
    Longo DL
    N Engl J Med; 2014 Dec; 371(23):2227-8. PubMed ID: 25470699
    [No Abstract]   [Full Text] [Related]  

  • 7. Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.
    Duruisseaux M; Besse B; Cadranel J; Pérol M; Mennecier B; Bigay-Game L; Descourt R; Dansin E; Audigier-Valette C; Moreau L; Hureaux J; Veillon R; Otto J; Madroszyk-Flandin A; Cortot A; Guichard F; Boudou-Rouquette P; Langlais A; Missy P; Morin F; Moro-Sibilot D
    Oncotarget; 2017 Mar; 8(13):21903-21917. PubMed ID: 28423535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
    Rodig SJ; Shapiro GI
    Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid response of brain metastasis to crizotinib in a patient with ALK rearrangement-positive non-small-cell lung cancer.
    Kaneda H; Okamoto I; Nakagawa K
    J Thorac Oncol; 2013 Apr; 8(4):e32-3. PubMed ID: 23486271
    [No Abstract]   [Full Text] [Related]  

  • 10. Hope without hype: EML4-ALK inhibition for treatment of lung cancer.
    Govindan R
    Lancet Oncol; 2011 Oct; 12(11):983-4. PubMed ID: 21933750
    [No Abstract]   [Full Text] [Related]  

  • 11. Treating ALK-positive lung cancer in the weeks after the FDA approval of crizotinib.
    Pennell NA
    Am J Manag Care; 2012 May; 18(5 Spec No. 2):SP84-7. PubMed ID: 22693986
    [No Abstract]   [Full Text] [Related]  

  • 12. New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer.
    Cameron L; Solomon B
    Curr Treat Options Oncol; 2015 Oct; 16(10):49. PubMed ID: 26318457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquired resistance to the ALK inhibitor crizotinib in the absence of an ALK mutation.
    Costa DB; Kobayashi S
    J Thorac Oncol; 2012 Mar; 7(3):623-5. PubMed ID: 22334013
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions.
    Cameron L; Solomon B
    Drugs; 2015 Jul; 75(10):1059-70. PubMed ID: 26076736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
    Hida T; Nokihara H; Kondo M; Kim YH; Azuma K; Seto T; Takiguchi Y; Nishio M; Yoshioka H; Imamura F; Hotta K; Watanabe S; Goto K; Satouchi M; Kozuki T; Shukuya T; Nakagawa K; Mitsudomi T; Yamamoto N; Asakawa T; Asabe R; Tanaka T; Tamura T
    Lancet; 2017 Jul; 390(10089):29-39. PubMed ID: 28501140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alectinib surpasses crizotinib for untreated ALK-positive NSCLC.
    Gilbert JA
    Lancet Oncol; 2017 Jul; 18(7):e377. PubMed ID: 28625556
    [No Abstract]   [Full Text] [Related]  

  • 17. [Crizotinib: At last in first-line treatment of advanced-stage ALK-rearranged non-small cell lung cancer].
    Giroux Leprieur E; Wislez M
    Bull Cancer; 2016 Feb; 103(2):125-6. PubMed ID: 26822904
    [No Abstract]   [Full Text] [Related]  

  • 18. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
    O'Bryant CL; Wenger SD; Kim M; Thompson LA
    Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus.
    Cappuzzo F; Moro-Sibilot D; Gautschi O; Boleti E; Felip E; Groen HJ; Germonpré P; Meldgaard P; Arriola E; Steele N; Fox J; Schnell P; Engelsberg A; Wolf J
    Lung Cancer; 2015 Feb; 87(2):89-95. PubMed ID: 25576294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?
    Toyokawa G; Seto T
    Clin Lung Cancer; 2014 Sep; 15(5):313-9. PubMed ID: 24984564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.